Hypoxia and Bortezomib Resistance in Chronic Myeloid Leukemia Stem Cells
Author Information
Author(s): Michele Tanturli, Serena Giuntoli, Valentina Barbetti, Elisabetta Rovida, Persio Dello Sbarba
Primary Institution: Dipartimento di Patologia e Oncologia Sperimentali, Università degli Studi di Firenze
Hypothesis
The study investigates the effects of hypoxia and the proteasome inhibitor Bortezomib on the maintenance of stem or progenitor cells in Chronic Myeloid Leukemia.
Conclusion
Hypoxia-adapted leukemia stem cells in Chronic Myeloid Leukemia are completely resistant to Bortezomib.
Supporting Evidence
- Hypoxia inhibits growth of CML cells and selects for stem cells that are resistant to Imatinib.
- Bortezomib treatment at different times affects the viability of CML cells in hypoxia.
- Hypoxia-selected stem cells show resistance to Bortezomib before and after their selection.
Takeaway
In a low-oxygen environment, some leukemia cells become strong and can resist treatment, making it harder to get rid of the disease.
Methodology
The study used a Culture-Repopulating Ability (CRA) assay to assess the effects of Bortezomib on K562 and primary CML cells in hypoxia.
Limitations
The study primarily focuses on in vitro conditions, which may not fully replicate in vivo environments.
Participant Demographics
The study included CD34-positive cells from blast-crisis CML patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website